For patients with advanced ovarian cancer, cytoreductive surgery (CRS) and platinum-based chemotherapy are pillars of treatment.1 Optimal completeness of cytoreduction, which may necessitate multivisceral resections, aims to achieve minimal residual disease and improve oncologic outcomes.2,3